SCHEMBL7150475

SCHEMBL7150475

CN(Cc1ccccc1)C(=O)[C@@H]1C[C@H](S)CN1C(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
RAB9A P51151 3/20 0.46
CPT2 P23786 1/20 0.42
CPT1A P50416 1/20 0.42
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
AGTR2 P50052 2/20 0.41
MLYCD O95822 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
MAOA P21397 1/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.38
UBE2M P61081 1/20 0.37
DCUN1D1 Q96GG9 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FFAR2 O15552 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135172 1.00 MEN1 (0.46) MEN1KMT2ARAB9ACPT2CPT1A
SCHEMBL7144151 0.86 SMN1; SMN2 (0.49) MEN1KMT2ACPT2CPT1ALMNA
SCHEMBL7137929 0.84 ACHE (0.46) RAB9ACPT2CPT1ATMEM97SIGMAR1
SCHEMBL7137783 0.81 CPT2 (0.48) KMT2ARAB9ACPT2CPT1AMAOA
SCHEMBL7141588 0.80 ALDH1A1 (0.47) MEN1KMT2ARAB9ACPT2CPT1A
SCHEMBL7137745 0.80 ALDH1A1 (0.47) MEN1KMT2ARAB9ACPT2CPT1A
SCHEMBL7140190 0.79 CPT2 (0.49) RAB9ACPT2CPT1AMAOAPOLB
SCHEMBL7143079 0.77 CPT2 (0.47) RAB9ACPT2CPT1ALMNAPOLB
SCHEMBL7144165 0.77 CPT2 (0.44) RAB9ACPT2CPT1APOLBNPC1
SCHEMBL7139208 0.76 CPT2 (0.46) RAB9ACPT2CPT1AAGTR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP MEN1 2985/4885KMT2A 1971/4885RAB9A 2425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.